Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03348631
Title Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

endometrioid ovary carcinoma

endometrial adenocarcinoma

ovarian clear cell carcinoma

peritoneal carcinoma

Therapies

Tazemetostat

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.